Streamex Corp. · NASDAQ:STEX
Streamex — BioSig Technologies — Investor Presentation (March 2019)
24 slides from Streamex's investor presentation, Mar 13, 2019
Slide 1: Investor Presentation Winter 2019
» Basis F Seed technologies’ gf Fy b. Presentation n Winter 2019 NASDAQ: BSGM
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new pr
Slide 3: BioSig Technologies at a Glance
BioSig Technologies at a Glance BioSig: First successful commercial use of PURE EP™ achieved FDA product clearance achieved; CE mark expected in 2019 Listed on the Nasdag Capital Market World-class management, board, advisors IP expertise from Sherpa Technology Group, Sterne Kessler 10-year strategi
Slide 4: Arrhythmia: A Challenging, Costly Disease
Arrhythmia: A Challenging, Costly Disease One-quarter of Americans will get irregular heartbeat Atrial Fibrillation Ventricular Tachycardia Affects 33.5M and between people... ae Much rarer, but responsible 2.7M and 6.1M for most sudden cardiac in the U.S. deaths in the U.S., ~300,000 per year Contr
Slide 5: Our First FDA-Approved Product: PURE EP System
Our First FDA-Approved Product: PURE EP™ System BioSig SYMBOL: : BSGM
Slide 6: First Successful Commercial Use of PURE EP
First Successful Commercial Use of PURE EP™ “With the use of the PURE EP™ System | was able to identify cardiac signals which were previously undetectable to me. | believe that the PURE EP™ System could change diagnostic and treatment strategies of arrhythmias, leading to more successful outcomes.”
Slide 7: PURE EP Value Proposition
PURE EP™ Value Proposition Potential benefits of PURE EP™ * Improves signal clarity, reduces “noise” CURRENT * May allowsurgeons to work more quickly and more accurately fold * May reduce likelihood/need for repeat procedure * Therefore, a better option for patients, py ly PUREEP™ physicians, and pa
Slide 8: Signal Clarity Paramount to Ablation Success
Signal Clarity Paramount to Ablation Success www.fda.gov SYMBOL: BSGM 8
Slide 9: PURE EP Developed Through Collaboration with Leading Centers of Excellence
PURE EP™ Developed Through Collaboration with Leading Centers of Excellence 2011 2013 2014 2014 2015 Concept developed Proof of concept test Prototype test Initial pre-clinical First pre-clinical with Texas Cardiac completed at UCLA with UCLA planning trials at Mayo Arrhythmia Institute at Mayo Clin
Slide 10: Market and Business Model
Market and Business Model Market Business Model * Global Electrophysiology (EP) + BioSig’s PURE EP™ System is market to reach $8.2B by sold as a hardware and 2022; registering a CAGR of software solution. 13.4% from 2016-2022. « The client purchases the * The Company also operates hardware and the s
Slide 11: Path to Commercialization
Path to Commercialization 2019 2020 2021 ee First installations at TCAI, Mayo Publish trial results Advance R&D, | Clinic for First-in-Human data bioelectronic medicine Expand PURE EP™ System Create cli I trial registry; Expand product pipeline develop clinical trial protocol Accelerate commercial p
Slide 12: Potential applications of PURE EP in neurology and ophthalmology
hardware configurations of the [PURE EP™]s m for mapping and reco! Ms signals in fields like neurology and ophthalmology, in orderto betterbe ableto — : characterize regional electrical activity.” — Authors of “Initial Experience with the BioSig PURE EP™ Signal Recording System: An Animal Laboratory
Slide 13: Our Vision: Leader in Bioelectronic Medicine
OUR VISION = lige Leader in Bioelectronic Meé ici A rapidly growing i, a is = that explores how targeteg ctrical signals e can harness the body’ s natural mechanisms to diagnose and treat a range of diseases SYMBOL: BSGM 13
Slide 14: Big Players Starting to Take Note
Big Players Starting to Take Note Tech giants exploring healthcare space Google @ amazon Sa ioSig: Medical device giants making investments fohmonafofmron Medtronic Bost Screntific Advancing science for life™ PHILIPS C) Abbott Successful 1POs, some with big-name funders We electroCore” “94 4@ Neuron
Slide 15: An Exciting, Fast-Growing Market
An Exciting, Fast-Growing Market Bioelectronic Medicine: Major Market Segments, 2017 Global Market Size, 2017: $20 BILLION 13 412 a 410 S 8 Abl Global Growth in EP a é Devices, 2016-24: 46 9 10.4% 0 = CardiacRhythm Electrophysiology Spinal Cord Deep Brain Management ‘Stimulation ‘Stimulation ‘Source
Slide 16: Unique Collaboration with Mayo Clinic
MAYO Unique Collaboration ri CLINIC with Mayo Clinic GY 10-year strategic agreement Explore new disease areas and - Defines collaborative work plan applications, leading to: - Spells out IP protection for both parties ~ Joint IP filings a - Licensing opportunities Develop advanced clinical features
Slide 17: Bioelectronic Medicine: Potential for Diagnosing and Curing Many Diseases
Slide 18: EP Sector M&A Activity
EP Sector M&A Activity Proof of Clinical CE Company Concept Prototype Data Mark FDA Sales investor Valuation aoe $94 million BioSig Technologies e . 2 © Feb 21, 2019 EPD Solutions $563 million Formed 2014 ° ° be = i PHILIPS June 2018 BD medtronic $1.4 Billion HeartWare . ° e e 0 ° June 2016 $80 mill
Slide 19: Robust IP Strategy, Supported by Experts
Robust IP Strategy, Supported by Experts inteD @ Sterne Cc *Kessler 2 STERNE KESSLER GOLDSTEIN & FOX BCG Te Boston Consuarive Grou faM_ [P Hail of Fame SYMBOL: BSGM 19
Slide 20: BioSig Investment Highlights
BioSig Investment Highlights BioSig: First successful commercial use of PURE EP™ achieved FDA product clearance achieved; CE mark expected in 2019 Listed on the Nasdag Capital Market World-class management, board, advisors IP expertise from Sherpa Technology Group, Sterne Kessler 10-year strategic c
Slide 21: Contact Us
Contact Us Ken Londoner Natasha Drapeau Founder, Chairman & CEO Executive Vice President +1 (203) 644-5200 +41 (0) 76 823 7527 klondoner@biosigtech.com ndrapeau@biosigtech.com ‘This document is being provided on a confidential basis by BioSig Technologies, Inc solely for the information of those per
Slide 22: Appendix
Appendix SYMBOL: BSGM
Slide 23: Seasoned Management Team
Seasoned Management Team Kenneth L. Londoner, MBA Founder, Chairman, CEO, Director Endicott Management Partners, LLC; J & W Seligman & Co. Natasha Drapeau Executive Vice President Institute of Directors, UK; Augeous Consulting, Switzerland; IG Group Pic, UK Steve Chaussy, CPA CFO Liberski Inc; Anna
Slide 24: World-Class Board of Directors
World-Class Board of Directors g Kenneth L. Londoner, MBA J. W, sca BioSig y aaa i «) | 2 a sens, IUBEAND yr FE seth. z.rischer Gohmonfohuon Wius e| PatrickJ.Gallagher, MBA,CFA — “cincutare™ Alftenex THERAPEUTICS Pharma Solitons |e | Jeffrey F. O’Donnell, Sr. a Boston, smbrelsF — Serentific Eq Andre
BioSig Technologies — Investor Presentation (March 2019) on 6ix